Literature DB >> 28434111

IDH mutation and 1p19q codeletion distinguish two radiological patterns of diffuse low-grade gliomas.

Amélie Darlix1,2, Jérémy Deverdun3, Nicolas Menjot de Champfleur3, Florence Castan4, Sonia Zouaoui5,6, Valérie Rigau7, Michel Fabbro8, Yordanka Yordanova9,10, Emmanuelle Le Bars3, Luc Bauchet9,6, Catherine Gozé9,11, Hugues Duffau9,6.   

Abstract

Diffuse low-grade gliomas (DLGG) prognosis is variable, depending on several factors, including the isocitrate dehydrogenase (IDH) mutation and the 1p19q codeletion. A few studies suggested associations between these parameters and tumor radiological characteristics including topography. Our aim was analyzing the correlations between the IDH and 1p19q statuses and the tumor intracerebral distribution (at the lobar and voxel levels), volume, and borders. We conducted a retrospective, monocentric study on a consecutive series of 198 DLGG patients. The IDH and 1p19q statuses were recorded. The pre-treatment magnetic resonance FLAIR imagings were reviewed for determination of lobar topography, tumor volume, and characterisation of tumor borders (sharp or indistinct). We conducted a voxel-based lesion-symptom mapping analysis to investigate the correlations between the IDH and 1p19q statuses and topography at the voxel level. The IDH mutation and 1p19q statuses were correlated with the tumor topography defined using lobar anatomy (p < 0.001 and p = 0.004, respectively). Frontal tumors were more frequently IDH-mutant (87.1 vs. 57.4%) and 1p19q codeleted (45.2 vs. 17.0%) than temporo-insular lesions. At the voxel level, these associations were not found. Tumors with sharp borders were more frequently IDH-mutant (p = 0.001) while tumors with indistinct borders were more frequently IDH wild-type and 1p19q non-codeleted (p < 0.001). Larger tumors at diagnosis (possibly linked to a slower growth rate) were more frequently IDH-mutant (p < 0.001). IDH wild-type, 1p19q non-codeleted temporo-insular tumors are distinct from IDH-mutant, 1p19q codeleted frontal tumors. Further studies are needed to determine whether the therapeutic strategy should be adapted to each pattern.

Entities:  

Keywords:  1p19q codeletion; Diffuse low-grade gliomas; IDH mutation; Molecular biology; Voxel-based lesion-symptom mapping

Mesh:

Substances:

Year:  2017        PMID: 28434111     DOI: 10.1007/s11060-017-2421-0

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  36 in total

1.  Voxel-based lesion-symptom mapping.

Authors:  Elizabeth Bates; Stephen M Wilson; Ayse Pinar Saygin; Frederic Dick; Martin I Sereno; Robert T Knight; Nina F Dronkers
Journal:  Nat Neurosci       Date:  2003-05       Impact factor: 24.884

2.  Mutational landscape and clonal architecture in grade II and III gliomas.

Authors:  Hiromichi Suzuki; Kosuke Aoki; Kenichi Chiba; Yusuke Sato; Yusuke Shiozawa; Yuichi Shiraishi; Teppei Shimamura; Atsushi Niida; Kazuya Motomura; Fumiharu Ohka; Takashi Yamamoto; Kuniaki Tanahashi; Melissa Ranjit; Toshihiko Wakabayashi; Tetsuichi Yoshizato; Keisuke Kataoka; Kenichi Yoshida; Yasunobu Nagata; Aiko Sato-Otsubo; Hiroko Tanaka; Masashi Sanada; Yutaka Kondo; Hideo Nakamura; Masahiro Mizoguchi; Tatsuya Abe; Yoshihiro Muragaki; Reiko Watanabe; Ichiro Ito; Satoru Miyano; Atsushi Natsume; Seishi Ogawa
Journal:  Nat Genet       Date:  2015-04-13       Impact factor: 38.330

3.  Imaging growth and isocitrate dehydrogenase 1 mutation are independent predictors for diffuse low-grade gliomas.

Authors:  Catherine Gozé; Marie Blonski; Guillaume Le Maistre; Luc Bauchet; Edouard Dezamis; Philippe Page; Pascale Varlet; Laurent Capelle; Bertrand Devaux; Luc Taillandier; Hugues Duffau; Johan Pallud
Journal:  Neuro Oncol       Date:  2014-05-20       Impact factor: 12.300

4.  Tumor location and growth pattern correlate with genetic signature in oligodendroglial neoplasms.

Authors:  M C Zlatescu; A TehraniYazdi; H Sasaki; J F Megyesi; R A Betensky; D N Louis; J G Cairncross
Journal:  Cancer Res       Date:  2001-09-15       Impact factor: 12.701

Review 5.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

6.  Evidence for potentials and limitations of brain plasticity using an atlas of functional resectability of WHO grade II gliomas: towards a "minimal common brain".

Authors:  Tamara Ius; Elsa Angelini; Michel Thiebaut de Schotten; Emmanuel Mandonnet; Hugues Duffau
Journal:  Neuroimage       Date:  2011-03-21       Impact factor: 6.556

7.  Dynamic history of low-grade gliomas before and after temozolomide treatment.

Authors:  Damien Ricard; Gentian Kaloshi; Alexandra Amiel-Benouaich; Julie Lejeune; Yannick Marie; Emmanuel Mandonnet; Michèle Kujas; Karima Mokhtari; Sophie Taillibert; Florence Laigle-Donadey; Antoine F Carpentier; Antonio Omuro; Laurent Capelle; Hugues Duffau; Philippe Cornu; Rémy Guillevin; Marc Sanson; Khê Hoang-Xuan; Jean-Yves Delattre
Journal:  Ann Neurol       Date:  2007-05       Impact factor: 10.422

8.  Correlations between molecular profile and tumor location in Chinese patients with oligodendroglial tumors.

Authors:  L Huang; T Jiang; F Yuan; G L Li; E Z Liu; Z C Wang
Journal:  Clin Neurol Neurosurg       Date:  2008-10-08       Impact factor: 1.876

9.  Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.

Authors:  G Kaloshi; A Benouaich-Amiel; F Diakite; S Taillibert; J Lejeune; F Laigle-Donadey; M-A Renard; W Iraqi; A Idbaih; S Paris; L Capelle; H Duffau; P Cornu; J-M Simon; K Mokhtari; M Polivka; A Omuro; A Carpentier; M Sanson; J-Y Delattre; K Hoang-Xuan
Journal:  Neurology       Date:  2007-05-22       Impact factor: 9.910

10.  Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas.

Authors:  Hinke F van Thuijl; Ilari Scheinin; Daoud Sie; Agusti Alentorn; Hendrik F van Essen; Martijn Cordes; Ruth Fleischeuer; Anja M Gijtenbeek; Guus Beute; Wimar A van den Brink; Gerrit A Meijer; Miek Havenith; Ahmed Idbaih; Khê Hoang-Xuan; Karima Mokhtari; Roel Gw Verhaak; Paul van der Valk; Mark A van de Wiel; Jan J Heimans; Eleonora Aronica; Jaap C Reijneveld; Pieter Wesseling; Bauke Ylstra
Journal:  Genome Biol       Date:  2014-09-23       Impact factor: 13.583

View more
  21 in total

Review 1.  IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis.

Authors:  Davide Tiziano Di Carlo; Hugues Duffau; Federico Cagnazzo; Nicola Benedetto; Riccardo Morganti; Paolo Perrini
Journal:  Neurosurg Rev       Date:  2018-06-26       Impact factor: 3.042

Review 2.  Neuro-Oncology and Radiogenomics: Time to Integrate?

Authors:  A Lasocki; M A Rosenthal; S J Roberts-Thomson; A Neal; K J Drummond
Journal:  AJNR Am J Neuroradiol       Date:  2020-09-10       Impact factor: 3.825

3.  Fully automated hybrid approach to predict the IDH mutation status of gliomas via deep learning and radiomics.

Authors:  Yoon Seong Choi; Sohi Bae; Jong Hee Chang; Seok-Gu Kang; Se Hoon Kim; Jinna Kim; Tyler Hyungtaek Rim; Seung Hong Choi; Rajan Jain; Seung-Koo Lee
Journal:  Neuro Oncol       Date:  2021-02-25       Impact factor: 12.300

4.  Neuroimaging-Based Classification Algorithm for Predicting 1p/19q-Codeletion Status in IDH-Mutant Lower Grade Gliomas.

Authors:  P P Batchala; T J E Muttikkal; J H Donahue; J T Patrie; D Schiff; C E Fadul; E K Mrachek; M-B Lopes; R Jain; S H Patel
Journal:  AJNR Am J Neuroradiol       Date:  2019-01-31       Impact factor: 3.825

5.  Tumor location and patient age predict biological signatures of high-grade gliomas.

Authors:  Roberto Altieri; Francesco Zenga; Alessandro Ducati; Antonio Melcarne; Fabio Cofano; Marco Mammi; Giuseppe Di Perna; Riccardo Savastano; Diego Garbossa
Journal:  Neurosurg Rev       Date:  2017-08-31       Impact factor: 3.042

6.  Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques.

Authors:  Maike Kern; Timo A Auer; Uli Fehrenbach; Yasemin Tanyildizi; Thomas Picht; Martin Misch; Edzard Wiener
Journal:  Neuroradiol J       Date:  2020-01-19

7.  Molecular classification of patients with grade II/III glioma using quantitative MRI characteristics.

Authors:  Naeim Bahrami; Stephen J Hartman; Yu-Hsuan Chang; Rachel Delfanti; Nathan S White; Roshan Karunamuni; Tyler M Seibert; Anders M Dale; Jona A Hattangadi-Gluth; David Piccioni; Nikdokht Farid; Carrie R McDonald
Journal:  J Neurooncol       Date:  2018-06-02       Impact factor: 4.130

8.  Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis.

Authors:  S C Thust; S Hassanein; S Bisdas; J H Rees; H Hyare; J A Maynard; S Brandner; C Tur; H R Jäger; T A Yousry; L Mancini
Journal:  Eur Radiol       Date:  2018-03-23       Impact factor: 5.315

Review 9.  Radiological differences between subtypes of WHO 2016 grade II-III gliomas: a systematic review and meta-analysis.

Authors:  Djuno I van Lent; Kirsten M van Baarsen; Tom J Snijders; Pierre A J T Robe
Journal:  Neurooncol Adv       Date:  2020-04-04

10.  Contrast-enhancement in supratentorial low-grade gliomas: a classic prognostic factor in the molecular age.

Authors:  Florian Castet; Enrique Alanya; Noemi Vidal; Cristina Izquierdo; Carlos Mesia; François Ducray; Miguel Gil-Gil; Jordi Bruna
Journal:  J Neurooncol       Date:  2019-05-03       Impact factor: 4.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.